Absci Corporation (ABSI)
NASDAQ: ABSI · IEX Real-Time Price · USD
4.615
-0.125 (-2.64%)
At close: May 17, 2024, 4:00 PM
4.600
-0.015 (-0.33%)
After-hours: May 17, 2024, 7:52 PM EDT
Company Description
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States.
The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.
The company was founded in 2011 and is headquartered in Vancouver, Washington.
Absci Corporation
| Country | United States |
| Founded | 2011 |
| IPO Date | Jul 22, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 155 |
| CEO | Sean McClain |
Contact Details
Address: 18105 Se Mill Plain Blvd Vancouver, Washington 98683 United States | |
| Phone | (360) 949-1041 |
| Website | absci.com |
Stock Details
| Ticker Symbol | ABSI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001672688 |
| CUSIP Number | 00091E109 |
| ISIN Number | US00091E1091 |
| Employer ID | 85-3383487 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Sean McClain | Founder, Chief Executive Officer, President and Director |
| Dr. Zachariah Jonasson Ph.D. | Chief Business Officer and Chief Financial Officer |
| Dr. Andreas Busch Ph.D. | Chief Innovation Officer and Member of Scientific Advisory Board |
| Todd Bedrick CPA | Senior Vice President and Chief Accounting Officer |
| Alexander Khan CPA | Vice President of Finance and Head of Investor Relations |
| Karin Wierinck | Chief People Officer |
| Melissa Patterson Ph.D. | Chief of Staff |
| Jens Plassmeier Ph.D. | Senior Vice President of Biologics Discovery Technology |
| Wen Sha | Chief of Staff |
| Dr. Christine Lemke D.V.M., M.B.A., Ph.D. | Senior Vice President of Portfolio and Growth Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 14, 2024 | 10-Q | Quarterly Report |
| May 14, 2024 | 8-K | Current Report |
| Apr 23, 2024 | ARS | Filing |
| Apr 23, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 21, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 21, 2024 | 10-K | Annual Report |
| Mar 21, 2024 | 8-K | Current Report |
| Mar 5, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 28, 2024 | 8-K | Current Report |